Finger Prick, Venous Blood Can ID Key Alzheimer Disease Biomarkers
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
THURSDAY, July 20, 2023 -- Finger prick or venous blood collection can identify key Alzheimer disease-related biomarkers, according to a study presented at the annual Alzheimer's Association International Conference, held from July 16 to 20 in Amsterdam.
Hanna Huber, Ph.D., from the University of Gothenburg in Sweden, and colleagues collected capillary dry blood spot (DBS[capillary]) and venous dry blood spot (DBS[venous]) as well as ethylenediamine tetraacetic acid (EDTA) plasma and neuropsychological measures from 43 memory clinic participants. Neurofilament light (NfL), glial fibrillary acidic protein (GFAP), and phosphorylated tau (p-tau) were measured by single molecular array. The researchers found that DBS(capillary) GFAP and NfL levels were associated with their counterparts in EDTA plasma. Significant associations were also seen for DBS(venous) GFAP, NfL, and p-tau181 with EDTA plasma levels. DBS(capillary) and DBS(venous) were associated with amyloid status; DBS(venous) NfL and p-tau181 were associated with Mini-Mental State Examination (MMSE), Clinical Dementia Rating (CDR), and amyloid.
In a second study, Huber and colleagues obtained DBS(capillary), DBS(venous), and EDTA plasma, and neuropsychological measures for 77 memory clinic participants. The researchers observed significant associations for DBS(capillary) GFAP and NfL with their counterparts in EDTA plasma. DBS(capillary) p-tau217, but not DBS(capillary) p-tau181, were associated with the same measures in EDTA plasma. DBS(venous) GFAP, NfL, p-tau217, and p-tau181 were also associated with their counterparts in EDTA plasma. DBS(capillary) GFAP and DBS(venous) GFAP, NfL, and p-tau181 were found to be associated with MMSE, CDR, and amyloid status.
"A method that allows blood collection at home and that is simple enough to be performed independently, or by caregivers, would increase accessibility of these tests," Huber said in a statement. "It would result in improved early diagnosis and better monitoring of patients considered 'at risk' or those who are receiving approved therapies."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted July 2023
Read this next
First Responders With More Debris Exposure Have Higher Risk of Early Dementia
FRIDAY, June 14, 2024 -- More severe exposure to dust or debris among World Trade Center (WTC) responders is significantly associated with a higher risk of dementia at <65...
1990 to 2019 Saw Increase in Life Expectancy in Seniors With T1DM
FRIDAY, June 14, 2024 -- From 1990 to 2019, there was an increase in life expectancy in older people with type 1 diabetes mellitus (T1DM), according to a study published online...
Second Tumors Are Rare After Chimeric Antigen Receptor T-Cell Therapy
FRIDAY, June 14, 2024 -- Second tumors are rarely seen after chimeric antigen receptor (CAR) T-cell therapy, according to a study published in the June 13 issue of the New England...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.